What is the recommended diagnostic workup and treatment plan for a patient with suspected mast cell activation syndrome (MCAS)?

Mast Cell Activation Syndrome (MCAS): Diagnostic Workup and Treatment

Diagnostic Approach

The diagnosis of MCAS requires meeting three specific criteria: (1) episodic symptoms involving at least two organ systems that are typical of mast cell activation, (2) objective biochemical evidence of mast cell mediator release, and (3) clinical response to antimediator therapy 1, 2.

Step 1: Clinical Presentation Assessment

Look for severe, episodic symptoms affecting multiple organ systems. The prototypical presentation is idiopathic anaphylaxis 3. Key manifestations include:

• Dermatologic: Flushing, pruritus, urticaria
• Cardiovascular: Tachycardia, hypotension, syncope
• Gastrointestinal: Abdominal cramping, bloating, diarrhea, nausea
• Respiratory: Bronchospasm, wheezing, throat swelling
• Neuropsychiatric: Headache, brain fog, anxiety

Critical pitfall: Symptoms must be episodic and severe—chronic, mild symptoms alone do not meet MCAS criteria 3.

Step 2: Exclude Secondary Causes

Before diagnosing MCAS, rule out:

• IgE-mediated allergies (particularly cofactor-dependent food allergy)
• NSAID hypersensitivity
• Other reactive causes of mast cell activation 3, 4

Step 3: Obtain Biochemical Evidence

The gold standard is demonstrating an acute increase in serum tryptase during an episode (sample drawn within 4 hours) compared to baseline, with the increase exceeding 20% + 2 ng/mL above baseline 2, 5.

Alternative approach if acute sampling is not feasible:

• Measure urinary metabolites (histamine, prostaglandin D2, leukotrienes) comparing baseline values with those obtained 3-6 hours post-event 3

Critical caveat: Elevated baseline tryptase or urinary mediators alone are NOT diagnostic of MCAS, nor do normal baseline values exclude the diagnosis 3.

Step 4: Evaluate for Clonal Mast Cell Disorders

In patients with idiopathic anaphylaxis or recurrent severe episodes:

• Measure baseline serum tryptase
• Test for KIT p.D816V mutation in peripheral blood using high-sensitivity assays
• Calculate a mast cell clonality prediction score (Spanish Network on Mastocytosis score) 3, 2
• Consider bone marrow biopsy if high probability of clonality 3

This distinguishes primary MCAS (clonal, KIT-mutated mast cells) from secondary or idiopathic MCAS 4.

---

Treatment Algorithm

Acute Episode Management

Patients with systemic anaphylaxis or airway angioedema must be prescribed an epinephrine autoinjector and trained on immediate use 1.

For acute episodes:

1. Epinephrine (intramuscular) for anaphylaxis, hypotension, or laryngeal edema
2. Supine positioning immediately for hypotensive episodes
3. Albuterol (inhaled) for bronchospasm
4. Transport to emergency department if epinephrine used 1

Preventive Pharmacotherapy

Begin with H1-antihistamines as first-line prophylaxis, then step up therapy based on symptom control 1.

First-Line Therapy

Nonsedating H1-antihistamines (fexofenadine, cetirizine):

• Start at standard dose, can increase to 2-4 times FDA-approved doses 1
• Preferred over first-generation antihistamines due to cognitive decline risk, especially in elderly 1

H2-antihistamines (famotidine, ranitidine):

• Use as first-line for gastrointestinal symptoms
• May help attenuate cardiovascular symptoms when combined with H1-blockers 1

Second-Line Therapy

Oral cromolyn sodium:

• Reduces abdominal bloating, diarrhea, cramps
• May benefit neuropsychiatric manifestations
• Use divided dosing with weekly upward titration to improve tolerance 1

Leukotriene inhibitors (montelukast) or 5-lipoxygenase inhibitors (zileuton):

• Consider particularly if urinary LTE4 levels elevated
• May reduce bronchospasm or GI symptoms 1

Additional Options for Refractory Cases

Aspirin (up to 650 mg twice daily):

• May reduce flushing and hypotension, especially with elevated urinary 11β-PGF2α
• Contraindicated in NSAID hypersensitivity—use with extreme caution 1

Omalizumab:

• Case reports show prevention of anaphylactic episodes in MCAS
• Consider for recurrent severe anaphylaxis 1

Corticosteroid burst (prednisone 0.5 mg/kg/day):

• Reserve for refractory symptoms
• Taper slowly over 1-3 months
• For procedures: 50 mg prednisone at 13,7, and 1 hour before intervention 1

Trigger Avoidance

Identify and avoid specific triggers:

• Insect venoms (consider lifelong venom immunotherapy for venom-sensitive patients) 1
• Temperature extremes
• Mechanical irritation
• Alcohol
• Specific medications (aspirin, radiocontrast agents, certain anesthetics) 1

---

Key Clinical Pearls

• Most patients have a favorable clinical course with appropriate management 3
• Combined forms of MCAS (clonal mast cells + IgE allergies + hereditary alpha tryptasemia) carry highest risk for life-threatening anaphylaxis 4
• Avoid first-generation antihistamines (diphenhydramine, hydroxyzine) in elderly due to cognitive decline risk and cardiovascular concerns 1
• Antihistamines work better as prophylaxis than acute treatment—once symptoms manifest, it's too late to block histamine-receptor binding 1